Preliminary evaluation of the impact of olanzapine/samidorphan on weight change in patients with schizophrenia or bipolar 1 disorder in a private practice setting.

Abstract: Objective: The prevalence of obesity and associated metabolic disorders in patients with schizophrenia or bipolar 1 disorder is approximately 60%. These comorbidities contribute to a 3-fold increase in mortality and a 15-year reduction in life expectancy contrasted to general population. We propose to compare results of 6 months treatment of olanzapine/samidorphan to 6 months treatment of olanzapine. Method: A retrospective chart review was conducted using a repeated measure study design. Metabolic effects, craving, smoking, efficacy, and safety were examined. Statistical analysis utilized ANOVA, Kruskal- Wallis, and Wilcoxon-Signed rank test for significance. Results: Nf44 patients with DSM-5 diagnosis for schizophrenia or bipolar 1 disorder. Patient demographics include: Age -41 + 9, African American (11%), Hispanic (9%), Caucasian (80%), male (52%), smoker (77%). Metabolic effects include weight (kg) (pre 86.1 +24.7 -post 80.5 +21.3, P 7% from baseline(P>.05), 29.5% lost >10 % from baseline(P.05), HbA1c (pre 5.1 +.25 – post 5.12 +.27, P>.05), and total cholesterol (pre 185.3 +24.9 – post 178.2 +22.5, P 10% of body weight after 6 months of treatment with olanzapine/samidorphan.Short Description: A preliminary evaluation of the impact of olanzapine/samidorphan on weight change in patients with schizophrenia or bipolar 1 disorder in a private practice setting. Our results provide evidence that olanzapine/samidorphan attenuates weight gain in outpatients currently treated with olanzapine. Moreover, a statistically significant number of patients (29.5%) lost > 10% of body weight after 6 months of treatment with olanzapine/samidorphan.Name of Sponsoring Organization(s): Geriatric Pharmacotherapy Institute, Inc.